Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)

Keros Therapeutics' Change in Account Payables history spans 7 years, with the latest figure at -$697000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 137.88% year-over-year to -$697000.0; the TTM value through Dec 2025 reached -$3.0 million, down 1105.22%, while the annual FY2025 figure was -$3.0 million, 1105.22% down from the prior year.
  • Change in Account Payables reached -$697000.0 in Q4 2025 per KROS's latest filing, up from -$3.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.7 million in Q2 2022 to a low of -$5.0 million in Q3 2022.
  • Average Change in Account Payables over 5 years is -$27950.0, with a median of -$79500.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: plummeted 774.73% in 2024, then surged 8678.26% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $823000.0 in 2021, then fell by 27.7% to $595000.0 in 2022, then soared by 75.46% to $1.0 million in 2023, then crashed by 128.07% to -$293000.0 in 2024, then plummeted by 137.88% to -$697000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Change in Account Payables are -$697000.0 (Q4 2025), -$3.0 million (Q3 2025), and -$1.4 million (Q2 2025).